Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: A single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 2005-2014

  Torkildsen, Gail ^a,b   O'Brien, Terrence P ^c  

^a Andover Eye Associates   (United States)

^b ORA Clinical Research and Development   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

azithromycin; conjunctiva; moxifloxacin; pharmacokinetics

Indexed keywords

AZITHROMYCIN; EYE DROPS; MOXIFLOXACIN;

ADULT; ARTICLE; BIOMICROSCOPY; CLINICAL TRIAL; CONJUNCTIVAL BIOPSY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SLIT LAMP; VISUAL ACUITY;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; AZITHROMYCIN; CHROMATOGRAPHY, LIQUID; CONJUNCTIVA; DIZZINESS; EYE HEMORRHAGE; FEMALE; HALF-LIFE; HUMANS; MALE; OPHTHALMIC SOLUTIONS; QUINOLINES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 57749188063     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.020     Document Type: Article

References (28)

1. Morrow G.L., and Abbott R.L. Conjunctivitis. Am Fam Physician 57 (1998) 735-746
2. Gigliotti F., Williams W.T., Hayden F.G., et al. Etiology of acute conjunctivitis in children. J Pediatr 98 (1981) 531-536
3. Kowalski R.P., Yates K.A., Romanowski E.G., et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112 (2005) 1987
4. Wagner R.S., Abelson M.B., Shapiro A., and Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 123 (2005) 1282-1283
5. Retsema J., and Fu W. Macrolides: Structures and microbial targets. Int J Antimicrob Agents 18 Suppl 1 (2001) S3-S10
6. AzaSite (azithromycin ophthalmic solution) [prescribing information]. Durham, NC: Inspire Pharmaceuticals, Inc; 2007.
7. Bowman L.M., E S., Pang J., and Friedlaender M. Development of a commercial eye drop formulation of azithromycin. Invest Ophthalmol Vis Sci. 48 (2007) B547 Abstract 772
8. Crean C., Vittitow J., Zink R.C., et al. Comparison of Azasite and azithromycin 1% for bacterial conjunctivitis. Poster. Presented at: American Society of Cataract and Refractive Surgeons 2008 Symposium (April 4-9, 2008) Chicago, Ill
9. Abelson M.B., Heller W., Shapiro A.M., et al. Clinical cure of bacterial conjunctivitis with azithromycin 1%: Vehicle-controlled, double-masked clinical trial. Am J Ophthalmol 145 (2008) 959-965
10. Abelson M., Protzko E., Shapiro A., et al. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol 1 (2007) 177-182
11. Blondeau J.M. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol 49 Suppl 2 (2004) S73-S78
12. Clinical study report C-01-401-003. Durham, NC: Inspire Pharmaceuticals, Inc; May 23, 2006.
13. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. (2006), Clinical and Laboratory Standards Institute (CLSI), Wayne, Pa Approved Standard
14. Romanowski E.G., Mah F.S., Yates K.A., et al. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am J Ophthalmol 139 (2005) 867-877
15. Alcon Inc. 2007 Annual Report.
16. (October 10, 2008). http://www.library.corporate-ir.net/library/13/130/130946/items/287541/2 007AR429.pdf Accessed
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6.
18. (September 9, 2008). http://www.ich.org/ Accessed
19. Welcome to MedDRA and the MSSO.
20. (October 8, 2008). http://www.meddramsso.com Accessed
21. The Uppsala Monitoring Center. WHO Drug Dictionary Enhanced.
22. (October 8, 2008). http://www.umc-products.com/DynPage.aspx?id=2829&mn=1107 Accessed
23. Burgess D.S. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115 Suppl 3 (1999) 19S-23S
24. Tabbara K.F., al-Kharashi S.A., al-Mansouri S.M., et al. Ocular levels of azithromycin. Arch Ophthalmol 116 (1998) 1625-1628
25. Kaur I.P., and Kanwar M. Ocular preparations: The formulation approach. Drug Dev Ind Pharm 28 (2002) 473-493
26. Si E.C., Bowman L.M., and Roy S.D. Ocular bioavailability and systemic levels of an ophthalmic formulation of azithromycin, ISV-401. Invest Ophthalmol Vis Sci. 44 (2003) B357 Abstract 1461
27. Smith A., Pennefather P.M., Kaye S.B., and Hart C.A. Fluoroquinolones: Place in ocular therapy. Drugs 61 (2001) 747-761
28. Vigamox (moxifloxacin) [product insert]. Fort Worth, Tex: Alcon Inc; 2003.